Effective immediately, the updated US childhood vaccine schedule will reduce the number of recommended vaccines for all children to 11 diseases, down from 18. On January 5, 2026, the CDC updated the ...

A look back at the FDA submissions and regulatory decisions in the pediatric health care space from December 2025. Another month has come and gone, and with it, several FDA approvals and regulatory ...

In this recap article, take a look back at some of our top stories in the infectious diseases space in 2025. Welcome to another edition of our Countdown to 2026! In this article, we take you through ...

Check out the top 5 nutrition articles of 2025. A case of painful plantar nodules in a 10-year-old boy following hot tub exposure was consistent with Pseudomonas hot-foot syndrome, a self-limited form ...

Check out the top 5 nutrition articles of 2025. A large observational cohort study conducted at Kaiser Permanente Northern California during the 2023–2024 RSV season found that nirsevimab was highly ...

Joshua Fitch is the senior editor for Contemporary Pediatrics. He joined the brand in March of 2023 as an editor before being promoted to senior editor in January 2024. Fitch graduated from Youngstown ...

Strategic Alliance Partnership | Contemporary Pediatrics connects pediatricians with peer-reviewed articles, guideline updates, and practice strategies for real-world clinical application.

Clinicians now have the first oral alternative to injectable therapy for gonorrhea, a shift Angela Hasler, APRN, CPNP-PC says could ease treatment barriers and improve public health outcomes.

Berotralstat becomes the first targeted oral prophylactic therapy for patients with HAE 2 years or older. The rare, inherited disease is characterized by unpredictable, potentially life-threatening ...

This approval of gepotidacin is the first in a new antibiotic class for the treatment of gonorrhoea approved in over 3 decades. Phase 3 data demonstrated noninferiority to ceftriaxone plus ...

Phase 3 results show oral zoliflodacin was noninferior to ceftriaxone and azithromycin for uncomplicated urogenital gonorrhea. Phase 3 trial showed non-inferiority of a single oral dose of ...